Subsequently, mirvetuximab soravtansine was approved by the US FDA for FRα‐positive platinum‐resistant epithelial ovarian, fallopian tube, or peritoneal cancer patients who had received 1–3 prior systemic therapies.254. Here, FOLR1 is linked to peritoneum cancer.